Autonomic

Tivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications

Retrieved on: 
Mercoledì, Maggio 22, 2024
Biotechnology, General Health, Health, Medical Devices, Consumer Electronics, Health Technology, Technology, Clinical Trials, Nervous system, Stroke, Medical research, Post-traumatic stress disorder, Heart, Autonomic nervous system, Depression, Conditional sentence, Autonomic, Migraine, Vagus nerve, Research, Epilepsy, Northwell Health, Cluster headache, Biomarker, Associate, VNS, Brain, Pharmaceutical industry

Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation (“ncVNS”).

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation (“ncVNS”).
  • The company has entered into a collaboration agreement with The Feinstein Institutes for Medical Research at Northwell Health to optimize its ncVNS device therapy for use in specific clinical indications.
  • Tivic Health will conduct a second 20-person clinical trial in collaboration with Theodoros Zanos, Ph.D., Associate Professor in the Institute of Bioelectronic Medicine and Head of the Neural and Data Science Lab at the Feinstein Institutes.
  • May 2024: Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (VNS); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

ScienceLogic Shares Bold Vision of Autonomic IT to Power the Autonomous Business

Retrieved on: 
Martedì, Maggio 14, 2024
Software, Networks, Internet, Electronic Design Automation, Artificial Intelligence, Data Management, Technology, Mobile, Wireless, Running, Automation, Organization, Investment, Ecosystem, Autonomic, Growth, SL1, Artificial intelligence, Generative, Acceleration, Synthetic media

ScienceLogic , a leader in automated IT operations, today unveils “ Autonomic IT ” — business-accelerating capabilities that combine data, artificial intelligence (AI) and automation.

Key Points: 
  • ScienceLogic , a leader in automated IT operations, today unveils “ Autonomic IT ” — business-accelerating capabilities that combine data, artificial intelligence (AI) and automation.
  • A novel approach to IT operations, Autonomic IT enables enterprises to focus on innovation, ensuring superior customer experiences and driving revenue growth by creating a cost-optimized, efficient, and scalable autonomous business.
  • Many enterprises strive to realize the promise of an autonomous business model but find themselves stalled due to high costs and low visibility from existing tools.
  • Powered by ScienceLogic’s SL1, customers can leverage the platform’s global visibility, advanced AI insights, and automation to deliver a state of autonomous business.

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Retrieved on: 
Mercoledì, Dicembre 13, 2023
Research, Neurology, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Medicine, Safety, Pain, Aes, Vertex, Pain management, Patient, TID, Week, Diabetic neuropathy, Medical Affairs Bureau, Autonomic, VRTX, DPN, Șaeș, Neuropathic pain, Vertex Pharmaceuticals, Pharmaceutical industry, Birth control

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).
  • The study also included an active reference arm of pregabalin to support the evaluation of the VX-548 treatment effect.
  • VX-548 was generally well tolerated at all doses tested in the study.
  • Most adverse events (AEs) were mild to moderate and there were no serious adverse events (SAEs) related to VX-548.

Cloud Computing Market worth $1,266.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Giovedì, Dicembre 7, 2023
Online, Berkshire Hathaway, Adobe, Final good, Disaster, Acquisition, Facial recognition, Internet of things, Shapeways, Organization, Software, Salesforce, Infrastructure as a service, MNM, IBM, Ocado, Cloud computing, CRM, Platform as a service, SME, Intelligence, Autonomic, Machine learning, Automation, Temple of Azure Clouds, IBM Consulting, Geographic Locator Codes, Partnership, Software as a service, Communication, Growth, ERP, AI, Microsoft, Walmart, Google Cloud, Alibaba Cloud, Video game, Mobile phone, Bank, Cloud, Service

The Cloud Computing Market is expanding, and vendors are adopting a strategic focus to attract customers.

Key Points: 
  • The Cloud Computing Market is expanding, and vendors are adopting a strategic focus to attract customers.
  • These services are increasing the demand for the Cloud Computing Market.
  • In recent years, cloud computing has emerged as a game-changing technology that significantly benefits the industry.
  • North America is estimated to account for the largest market share in the global Cloud Computing Market in 2023, and this trend will continue during the forecast period.

Cloud Computing Market worth $1,266.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Giovedì, Dicembre 7, 2023
Online, Berkshire Hathaway, Adobe, Final good, Disaster, Acquisition, Facial recognition, Internet of things, Shapeways, Organization, Software, Salesforce, Infrastructure as a service, MNM, IBM, Ocado, Cloud computing, CRM, Platform as a service, SME, Intelligence, Autonomic, Machine learning, Automation, Temple of Azure Clouds, IBM Consulting, Geographic Locator Codes, Partnership, Software as a service, Communication, Growth, ERP, AI, Microsoft, Walmart, Google Cloud, Alibaba Cloud, Video game, Mobile phone, Bank, Cloud, Service

The Cloud Computing Market is expanding, and vendors are adopting a strategic focus to attract customers.

Key Points: 
  • The Cloud Computing Market is expanding, and vendors are adopting a strategic focus to attract customers.
  • These services are increasing the demand for the Cloud Computing Market.
  • In recent years, cloud computing has emerged as a game-changing technology that significantly benefits the industry.
  • North America is estimated to account for the largest market share in the global Cloud Computing Market in 2023, and this trend will continue during the forecast period.

BT and Google Cloud Advance Cybersecurity With New Partnership

Retrieved on: 
Mercoledì, Ottobre 11, 2023
Cloud, Partnership, Chronicle, Intelligence, Security, Risk management, AI, Google Cloud, Cyberattack, BT Enterprise, ASO, Google Cloud Platform, Public sector, Autonomic, BT Group, Security Advisory Services, BT, Face, BigQuery, Mobile phone, Network equipment provider, Looker

BT announces new strategic security partnership with Google Cloud, targeting a range of joint innovation opportunities.

Key Points: 
  • BT announces new strategic security partnership with Google Cloud, targeting a range of joint innovation opportunities.
  • LONDON and SUNNYVALE, Calif., Oct. 11, 2023 /PRNewswire/ -- BT and Google Cloud today announced a new partnership focusing on an enhanced commitment to cybersecurity innovation.
  • The partnership builds on BT Group and Google's existing relationship to house BT Group's data in Google Cloud to support its analytics and AI ambitions.
  • BT and Google Cloud will also seek to incorporate solutions from Mandiant, a market leader in threat intelligence solutions acquired by Google in 2022, as an additional aspect of the partnership.

URC and the Custom Installation Industry Celebrate the 9th Annual Unsurpassed Awards

Retrieved on: 
Giovedì, Settembre 7, 2023
Lighting, Paradigm, Human, HDA, Total, Autonomic, International, Academy Award for Best International Feature Film, Joel Spira (businessman), Sennheiser, Aesthetics, Potter, Samsung, CIS, Automation, Element, History, Creativity, Via, HVAC, URC, Total Control, Apple, LG, System, Sensation, Mobile phone, Auction, Tenterden, CEDIA

HARRISON,N.Y., Sept. 7, 2023 /PRNewswire-PRWeb/ -- URC, a global leader in smart home automation and control for residential and commercial applications, announced today, from CEDIA, the winners of its 9th annual Unsurpassed Awards.

Key Points: 
  • HARRISON,N.Y., Sept. 7, 2023 /PRNewswire-PRWeb/ -- URC, a global leader in smart home automation and control for residential and commercial applications, announced today, from CEDIA, the winners of its 9th annual Unsurpassed Awards.
  • Mr. Chang K. Park, URC's Founder and CEO
    Launched in 2014, URC's Unsurpassed Awards celebrate excellence and creativity in residential and commercial automation installations.
  • Entries include inspiring environments and large installations with URC's Total Control® controlling hundreds of smart home and commercial devices.
  • Winners of the 2023 URC's Unsurpassed Awards include the following URC dealers:
    Custom Integrated Solutions (Youngstown, OH) http://www.cisohio.com/ A first-time winner takes the top prize for an incredible residential installation.

CND Life Sciences Enters into Licensing and Collaboration Agreement to Advance Diagnostic Technology for Neurodegenerative Diseases

Retrieved on: 
Mercoledì, Marzo 22, 2023
CND, Autonomic, Therapy, Beth Israel Deaconess Medical Center, Research, Doctor of Philosophy, Disorder, Dementia, Parkinson's disease, MD, Patient, Frustration, Neuroscience, Alpha-synuclein, Lewy body, Diagnosis, Health, Synucleinopathy, Alzheimer's disease, Skin, Caregiver, Pharmaceutical industry, PHOENIX

PHOENIX and BOSTON, March 22, 2023 /PRNewswire/ -- CND Life Sciences, a medical technology company pioneering the development of highly accurate skin-based tests to help clinicians diagnose neurodegenerative disorders like Parkinson's disease and dementia with Lewy bodies, has entered into a licensing collaboration with Beth Israel Deaconess Medical Center (BIDMC) in Boston to advance CND's scientific platform and patient-focused mission.

Key Points: 
  • Additionally, CND and BIDMC are exploring opportunities to identify other protein markers in the skin that are pathological hallmarks of other neurodegenerative diseases.
  • The lack of diagnostic certainty can lead to unnecessary tests, frustration by patients and caregivers, and suboptimal care.
  • "BIDMC looks forward to working with CND in the field of neurobiology," said Gyongyi Szabo, MD, PhD, Chief Academic Officer of BIDMC.
  • "Technological breakthroughs in neurodegeneration diagnosis and treatment should substantially improve patient care in the next decade."

AUTONOMIC launches Fellowship Program for founders and their teams who have been impacted by the Silicon Valley Bank failure

Retrieved on: 
Martedì, Marzo 21, 2023
Uncertainty, Silicon, Silicon Valley Bank, Research, SVB, Multimedia, Mobile phone, Cryptocurrency, Online shopping, Autonomic

The fellowship program is designed specifically to support founders and their teams manage stress and optimize overall brain performance during this turbulent time.

Key Points: 
  • The fellowship program is designed specifically to support founders and their teams manage stress and optimize overall brain performance during this turbulent time.
  • "Under the current circumstances with Silicon Valley Bank (SVB) founders need to come together and support one another in the ways we best know how.
  • The fellowship program is open to founders from all industries and backgrounds who have been impacted by the (SVB) failure.
  • For more information about the fellowship program, including eligibility requirements and application details, visit Autonomic's website at www.getautonomic.com/fellowship
    View original content to download multimedia: https://www.prnewswire.com/news-releases/autonomic-launches-fellowship-p...

Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System

Retrieved on: 
Mercoledì, Novembre 2, 2022
American Autonomic Society, AAS, Center, Clinical trial, Parkinson's disease, Autonomic nervous system, Biopharma LLC, NASDAQ, Company, Pure autonomic failure, Autonomic, Patient, Multiple system atrophy, Noh, International Symposium on Endovascular Therapy, 2021 Essex County Council election, Drug development, Bachelor of Medicine, Bachelor of Surgery, LS, Quality of life, Beth Israel Deaconess Medical Center, Orthostatic hypotension, MSA, Caregiver burden, Pharmaceutical industry, Hydraulic machinery, Neurology

DUBLIN, Nov. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc.("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).

Key Points: 
  • DUBLIN, Nov. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc.("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).
  • Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic nOH in patients with multiple system atrophy (MSA).
  • "These ampreloxetine data are encouraging for patients with MSA suffering with neurogenic orthostatic hypotension.
  • MSA is a progressive brain disorder that affects movement and balance and disrupts the function of the autonomic nervous system.